Navigation Links
ActivBiotics Assignee Issues First Distribution of Cash to Creditors
Date:6/19/2008

WELLESLEY HILLS, Mass., June 19 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") the Assignee for the Benefit of Creditors of ActivBiotics, Inc. ("ActivBiotics") announced today the first distribution of cash to the creditors of ActivBiotics. The distribution signifies the substantial completion of the asset liquidation process and the allowance of creditors' claims. The assignment, which began the liquidation process, was a transfer of all the assets of ActivBiotics to Finn on December 7, 2007, under a common law procedure. The process was complex because ActivBiotics was a biotech start-up company with sophisticated intellectual property and fixed assets.

Finn pointed out that the assignment process allowed him to move quickly and that the distribution of cash to creditors six and a half months after the process began highlights one of the major benefits of the assignment legal process for liquidating defunct enterprises.

Finn praised the law firm he retained to assist him, Bingham McCutchen LLP, to include, but not be limited to, Edwin Smith, Meerie Joung and Jennifer Cleary.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr. is the founding partner of the firm Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-four (34) years.


'/>"/>
SOURCE ActivBiotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
2. ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer
3. ActivBiotics Set to Sell Proprietary Assets, Including Drug Product Candidates, on March 14, 2008
4. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
5. ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
6. Neuftec Issues Patent Infringement Proceedings in the UK Against Oxonica
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
8. Bristol-Myers Squibb Issues $1.6 Billion of Senior Notes
9. SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT
10. VaxGen Issues Rebuttal to MedCap Letter
11. pH Balanced RepHresh Vaginal Gel(R) now Available to Women in Canada Attacking Tough, Embarrassing Feminine Issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake Lubinski, describes ... characteristics when deformed, which is identical to how the human discs work to ... and return to its natural state along a hysteresis curve, exactly like a ...
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... York , March 23, 2017 According ... plasma products and derivatives market is fragmented due to the presence of ... such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with ... these three companies, collectively, held more than 76% of this market ... As ...
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers face a ... lab samples to full-size tissues, bones, even whole organs to implant in people ... delivers blood deep into the developing tissue. , Current bioengineering techniques, including ...
Breaking Biology Technology:
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
Breaking Biology News(10 mins):